David Darling has a dig at DHB delays

David Darling has a dig at DHB delays
David Darling: Disappointed with slow adoption (Image: Supplied)
Brent Melville
Pacific Edge’s cancer diagnostic products have made headway into the US healthcare sector over the past several years, but many New Zealand patients continue to be shut out by the bureaucracy of local DHBs, the company says.Last June, the NZX-listed firm announced giant US healthcare group Kaiser Permanente had approved its Cxbladder products for use by urologists to monitor patients for bladder cancer. A month later it announced Cxbladder tests will be covered by the Centers for Medicare and Medicaid Services (CMS) across the US mar...

More Markets

NZ sharemarket celebrates a near 1% Easter rise
Markets Market close

NZ sharemarket celebrates a near 1% Easter rise

The S&P/NZX 50 Index closed at 12,105.29, up 94.62 points or 0.79%.

F&P Healthcare facing $12m bill for product recall
Markets

F&P Healthcare facing $12m bill for product recall

The company will provision the cost in its next full year results.

Synlait seeking help from major shareholder for $130m debt
Markets

Synlait seeking help from major shareholder for $130m debt

Synlait enters trading halt as it needs more time to come up with cash.